King Pharmaceuticals Inc.: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for King in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

* Gain insight into King's strategic outlook across the next 6 years
* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for King over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

* Benchmark King's performance against key rivals in the prescription pharmaceutical sector
* See how King, having suffered a period of declining sales, will return to positive growth over the forecast period
[Studien Infos ausblenden]

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Operating costs and profit analysis
King Pharmaceuticals: PharmaVitae forecasts at a glance
Strategic insight
Challenging times as key products face generic competition
Pfizer acquisition of King expands its presence in the pain market
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest prescription pharma product news
Q4 2010
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Latest corporate news
Q3 2010
Q2 2010
Q1 2010
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Elan deal creates life after Altace
Mylan acquisition failed to materialize
Alpharma acquisition completed in December 2008
Pfizer acquires King
Current corporate structure
Pharmaceuticals business unit structure
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Launch analysis, 2009–15
Core analysis, 2009–15
Expiry analysis, 2009–15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS
Key findings
Overview
Central nervous system
Remoxy
Embeda
Flector
Acurox
Immunology and inflammation
EpiPen
Diractin
APPENDIX
R&D pipeline
References
Abbreviations
[Inhaltsverzeichnis ausblenden]